This press release contains forward-looking statements.
The company assumes no forward-looking statements forward-looking statements new information, events new information, events or circumstances after the date reflect reflect the occurrence of unanticipated events.. This press release contains forward-looking statements, including statements regarding the Company’s results of clinical trials, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in the development and marketing strategy. The Company’s actual results to differ materially from those that are associated with these forward-looking statements on a number of factors, including risks and uncertainties associated with the Company’s research and development activities specified, the results of clinical trials, the receipt and timing of FDA and other regulatory approvals, market acceptance of the Company’s products on offer, the company expected operating losses, need for future capital and ability obtain future funding, competition from third parties, ability of the company ability of the company and to protect intellectual property pany’s dependence on third-party manufacturers and suppliers, the company’s lack of sales and marketing experience ability of the Company ability of the Company and to hold, changes in technology, government regulation and general market conditions and the risks and uncertainties in the Company’s current and periodic reports with the Securities and Exchange Commission , including the company’s Annual Report on Form 10 – K for the year ended 31 December 2008.
-ans have the disease, which affects all age groups. It is 10 to 15 times more common in women than adult men. Wakeland research team identified a cluster of genes family SLAM/CD2 that in the same region of the human genome associated with genetic susceptibility to the disease. Genes play a crucial role in the development of the disease in the mice, but only if they are expressed in certain combinations with other genes.
‘The SLAM/CD2 family interacts with sets of highly variable genes, which may path toward path toward disease,’said Dr. Wakeland.In addition, the researchers linked this gene family to resistance to infectious diseases. The latest findings follow an earlier discovery by Dr.BIDMC accede to in association with Brigham and Women’s Hospital, which IPFnet was the first Boston-area page, explains Principal Investigators Joseph Zibrak, member of the BIDMC Division of Pulmonary and Critical Care Medicine. Because these pulmonary condition continue to relate to a large number of people, we are pleased be capable to our patients chance to participate in the clinical research try out new test new and promising therapies. .. Boston-area Deaconess Medical centers join Idiopathic Pulmonary Fibrosis Clinical Research NetworkBeth Israel Deaconess Medical Center will Idiopathic Pulmonary Fibrosis Clinical Research Network , a clinical research, Avatar Join sponsored the National Heart Lung and Blood Institute to assess for the conduct of randomized clinical study on new and existing medications for the treatment by idiopathic pulmonary fibrosis .
The IPFnet in 2005 in 2005 effective effective therapy for patients with both early and advanced stages this devastating illness, and IPFnet IPFnet, BIDMC take in these clinical studies. For many years, BIDMC is a leading enterprise in carrying out clinical trials for IPF therapies, including experiments drugs such as interferon-gamma, pirfenidone and bosentan testing, says Zibrak. Expand The IPFnet continued prospects for our patient and improve communication by doctors and health centers throughout the country at the tip of at the forefront of treating people with this disease..